Specialist radiochemistry and medical imaging consultancy supporting pharma, biotech, imaging CROs and academic centres - from tracer strategy and lab design to regulatory execution and clinical optimisation.
About CITRAS
With a combined experience in excess of 70 years, CITRAS brings together a unique knowledge base across scientific, operational and business excellence in the fields of nuclear medicine and molecular imaging. In addition to its leadership, CITRAS is home to world class scientific and operational consultants with global experience and prides itself on the ability to connect. With a focus on partnership in service delivery, CITRAS is ready to offer support tailored to your needs.
The Challenge We Are Facing
We are living through an unprecedented period of growth in the development and prescription of radiopharmaceuticals. The drivers for this are clear – these drugs are true theranostics, enabling targeted and personalised molecular-level diagnosis and treatment.
This represents a significant step forward from traditional chemotherapy, minimising side-effects by delivering radiation precisely and directly to the target cells and minimising collateral damage to surrounding, healthy cells. The systemic reach of these drugs is significant, and the development of Beta and Alpha-emitting radionuclides increases our ability to destroy treatment-resistant tumours whilst protecting healthy tissues.
This growth in the development and application of isotope-labelled medicines has created supply chain issues in the drug development space – the level of innovation in the use of these tools has out-stripped the development of the ecosystem needed to provide timely support to these developments.
CITRAS was founded to address this challenge.
Traditional CDMO infrastructure was designed to support large-scale demand for a limited number of established imaging tracers (18F, 99mTc, 111In, 123I) and a small set of therapeutic isotopes (primarily 177Lu, 131I and 227Ra). As opportunities for radiopharmaceutical therapies expand, the industry is adapting to rapidly increasing demand for new diagnostic and therapeutic compounds - a shift that will take time, with many stakeholders still lacking established relationships with CDMOs.
Academic institutions remain a critical source of innovation, providing access to novel tracers and early-stage development capabilities. However, this landscape is fragmented and can be difficult to navigate, particularly when aligning with the quality and production standards required for clinical trials.
The result is a disconnected ecosystem - characterised by long lead-times for radioligand identification, supply chain inefficiencies, and delays in progressing drug development programmes.
CITRAS was founded to address these challenges. With over 70 years of combined experience across radiochemistry, clinical trials, and operational delivery, the team provides end-to-end expertise - from facility design and labelling feasibility through to isotope selection, CMC development, supply chain strategy, and clinical site implementation.
Our Services
Who We Work With
Pharma and Biotech companies developing radiopharmaceutical or imaging-dependent assets
Imaging CROs seeking specialist radiochemistry input
CDMOs requiring technical and strategic collaboration
Academic institutions establishing radiochemistry and molecular imaging capability
Our People
Jan Passchier
Senior business leader with 30+ years experience in radiochemistry and the operations and application of molecular imaging in support of drug development and disease understanding
CSO, co-founder
Fiona Roberts
Senior Operational leader with over 25 years experience in Molecular Imaging, with over 10 years dedicated to leadership of research imaging services and radioligand manufacturing.
COO
Roughan Sheedy
Life sciences exec with over 25 years experience in the sector, including 15 years supporting and leading imaging CRO businesses.